Amgen and Pfizer-backed oncology therapy developer NexImmune has filed to raise up to $86.3m in an IPO on the Nasdaq Global Market.

Invenergy unit Energize Ventures returned for a series D round that lifted the electric vehicle charger provider's total equity funding to $200m.

Novo and Pfizer are among the investors set to exit the cancer therapy developer, which has set a $100m target for its initial public offering.

GV-backed Aledade has secured series D funding at a $2.2bn post-money valuation to build out the business model for its primary care network.

Bennett Coleman & Co, Globe Telecom and Tencent are set to exit the story sharing community operator in a cash-and-stock acquisition transaction by Naver.

Lilly Asia Ventures is the largest shareholder of liver disease therapy developer Terns, which closed a $97.7m round earlier this month.

The Dell and Orr Partners-backed cloud software developer has collected $54m in a round co-led by Greenfield Partners and Jerusalem Venture Partners.

Columbia University is in line for an exit as cancer drug developer Vor files for its initial public offering.

Novo and GV participated in a round that lifted the Harvard, Broad Institute and Penn-linked heart disease drug developer's overall funding to more than $215m.

Amazon returned for a round valuing the electric truck developer at $27.6bn as it prepares to release its first vehicles later this year.